MELLPRO MAP Recombinant Mussel Adhesive Protein is developed via genetic engineering based on the underwater super-adhesion mechanism of marine mussels, rich in characteristic L-DOPA functional catechol groups.
Under cutaneous physiological conditions, it rapidly self-crosslinks into a dense, water-resistant, and breathable protective biopolymer film. It effectively shields vulnerable skin from friction, pollutants, and chemical irritants, calming redness and heat, accelerating post-sun recovery, and offering distinctive barrier defense in dermatological creams.
Elastic Recoil Model
Recombinant tropoelastin cross-linking with microfibrils rebuilding skin 3D recoil network.
RAW MATERIAL TECHNICAL & REGULATORY DOSSIER
Comprehensive Technical, Quality Specification, and Regulatory Dossier for R&D Formulators, Procurement, and Product Managers
📊
Biotechnology Mechanism & Scientific Evidence
Authoritative Brochure Technical Diagram · Molecular Model · Transdermal & Efficacy Mechanism
Mechanism DiagramRecombinant tropoelastin cross-linking with microfibrils to build dermal elasticity 3D recoil network.
🔬
Formulation R&D Engineer Guide (R&D Technical Dossier)
Formulation Application · Physicochemical Parameters · Stability & Compatibility
| INCI Name (CN) |
MusselExtract物、1,2-1,2-Hexanediol, Aqua |
INCI Name (EN) |
Mussel Extract, 1,2-Hexanediol, Aqua |
| CAS No. |
6920-22-5 / 7732-18-5 |
Recommended Dosage |
0.2% - 2.0%（ aqua become Soothing 0.3% - 1.0%） |
| Optimal pH Range |
5.0 - 6.5 |
Thermal Processing |
Add below 40°C during final formulation phase |
| Appearance & Odor |
Colorless to pale straw clear liquid |
Solubility & Method |
Readily soluble in water phase |
💡 Compatibility Guidelines & Precautions: Avoid strong alkaline conditions (pH >7.5) to prevent DOPA auto-oxidation
📦
Procurement & Compliance Dossier (Procurement & Compliance)
NMPA Code · MOQ · Sampling Support · Certificate of Analysis
| NMPA Submission Code |
✓ 177543-00075-8859 |
Supply Packaging |
1kg/fluorinated bottle, 5kg/drum, 20kg/drum |
| Minimum Order Quantity (MOQ) |
1 kg (Ready Stock) |
Delivery Lead Time |
Dispatched within 24-48 hours |
| Storage Conditions |
Store refrigerated at 2-8°C, protected from light |
Shelf Life (Shelf Life) |
24 Months |
| R&D Sample Support |
Complimentary 30g trial sample with application protocols |
Quality Documentation |
Batch COA, SDS, TDS, Wet Surface Adhesion & Safety Reports |
💡
Product Planning & Marketing Highlights (Marketing Highlights)
Core Mechanism · Efficacy Claims · Recommended Formats · Scientific Backing
🧬 Core Bio-Tech Barrier & Mechanism of Action:
DOPA moieties undergo rapid coacervation on moist skin surfaces, creating a microscopic, flexible, bio-adhesive protective mesh that shields nerve endings, accelerates re-epithelialization, and quenches inflammatory cascades.
✨ Key Selling Point Keywords:
🏷️ Biomimetic Breathable Shield🏷️ Intensively Soothing Redness & Itchiness🏷️ Compromised Skin Post-Care🏷️ Blocking Airborne Particulate Stress🏷️ Fortifying Damaged Lipid Barrier
🧴 Recommended Product Formats & Categories:
Medical aesthetic post-laser dressings, redness relief sprays, sensitive barrier rescue serums, anti-itch creams
📜 Patented Technologies & Scientific Backing:
Granted Invention Patent on Recombinant Mussel Adhesive Protein Synthesis
⚖️
Regulatory Compliance & Peer-to-Peer Disclaimer
Regulatory & Professional Compliance Statement:
1. The raw material characteristics and experimental data (including cytological studies, mechanism diagrams, and literature citations) presented on this webpage are intended exclusively for technical discussion and formulation R&D reference by cosmetic brand formulators, R&D engineers, product planners, and academic research institutions. They do not constitute finished consumer cosmetic efficacy claims or commercial warranties.
2. Pursuant to the Regulations on the Supervision and Administration of Cosmetics, Standards for Cosmetic Efficacy Claim Evaluation, and relevant global cosmetic regulatory frameworks, cosmetic brand enterprises utilizing this raw material shall be solely responsible for the safety, stability, and efficacy claims of their finished consumer products, and shall independently complete efficacy evaluations and regulatory filings/registrations with the competent health authorities prior to commercial launch. Conclusions from in-vitro or cellular studies shall not be directly extrapolated as consumer claims.
3. Mellgen Biotech assumes no joint or indirect liability for any claims or regulatory non-compliance arising from improper customer formulation, unauthorized off-label claims, or unverified applications.
